From October 1, 2023 to December 18, 2023, the company has repurchased 73,300 shares, representing 0.62% for CAD 0.62 million. With this, the company has completed the repurchase of 380,000 shares, representing 3.17% for CAD 2.89 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9 CAD | 0.00% | +9.22% | -2.39% |
May. 17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 17 | BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.39% | 76.26M | |
+37.74% | 723B | |
+32.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.60% | 244B | |
+9.77% | 208B | |
-5.15% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.